A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Pliant Therapeutics, Inc.
Pfizer
Genentech, Inc.
National Cancer Institute (NCI)
Vividion Therapeutics, Inc.
Erasca, Inc.
Novartis
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Pfizer
Dana-Farber Cancer Institute
Sutro Biopharma, Inc.
Tizona Therapeutics, Inc
Amgen
IDEAYA Biosciences
Eli Lilly and Company
Novartis
Amgen
Sairopa B.V.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tempest Therapeutics
Valo Therapeutics Oy
Epkin
Bicara Therapeutics
Xencor, Inc.
Incyte Corporation
Toray Industries, Inc
Trishula Therapeutics, Inc.
DEKA Biosciences
Boehringer Ingelheim
Turnstone Biologics, Corp.
Merck Sharp & Dohme LLC
Carisma Therapeutics Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Astellas Pharma Inc
NGM Biopharmaceuticals, Inc
Adlai Nortye Biopharma Co., Ltd.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Ikena Oncology
Wellmarker Bio
Stingthera, Inc.
Hefei TG ImmunoPharma Co., Ltd.
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Emory University